Axa
SGMO

Axa’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Axa’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-458,600
Closed -$596K – 1148
2023
Q2 		$596K Buy
+458,600
New +$627K ﹤0.01% 926
2023
Q1 		– Sell
-291,800
Closed -$916K – 1177
2022
Q4 		$916K Hold
291,800
– – ﹤0.01% 901
2022
Q3 		$1.43M Buy
+291,800
New +$1.5M 0.01% 810
2021
Q1 		– Sell
-48,100
Closed -$751K – 1320
2020
Q4 		$751K Buy
48,100
+35,000
+267% +$410K ﹤0.01% 1019
2020
Q3 		$124K Buy
13,100
+1,300
+11% +$14.1K ﹤0.01% 1180
2020
Q2 		$106K Buy
+11,800
New +$109K ﹤0.01% 1203

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Axa's SGMO Position: Q3 2023 in Review

Axa sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2023, closing a stake of 458,600 shares — an estimated $596K sold.

Axa first reported a position in SGMO in Q2 2020 and held it in 6 quarters. The position peaked at $1.43M in Q3 2022. 134 funds tracked by Wall St. Rank hold SGMO as of Q3 2023.

  • Axa reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
  • Axa sold 458,600 SANGAMO THERAPEUTICS INC shares in Q3 2023, an estimated $596K.
  • Axa first reported a position in SANGAMO THERAPEUTICS INC in Q2 2020 and held it in 6 quarters.
  • Axa's SANGAMO THERAPEUTICS INC position peaked at $1.43M in Q3 2022.
  • 134 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.